Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Sub-Visible Particles: Impact On Therapeutic Proteins

Published: Friday, June 07, 2013
Last Updated: Friday, June 07, 2013
Bookmark and Share
New LyoLearn webinar to run on 27th June 2013.

SP Scientific has announced a new LyoLearn webinar, due to run on 27th June 2013, entitled 'Sub-visible Particles: Impacts on Aggregation Pathways, Adverse Immunogenicity and Regulatory Expectations for Therapeutic Proteins'.

During the session, Dr. John Carpenter Professor of Pharmaceutical Sciences and Co-Director of the Center for Pharmaceutical Biotechnology, University of Colorado (USA), discusses key areas and presents the latest results from his research.

In addition, he will highlight the particle counting instruments that have been vital to the progress made to date.

Over the past several years there has been greatly increasing attention on sub-visible particles in therapeutic protein products.

Initially, much of the discussion and debate in the field has centred on the utility and need for quantifying particles smaller than 10 micron.

As appropriate instruments and quantitative methods have been developed, valuable progress has occurred in a wide range of drug development areas and more clearly defining critical quality attributes and regulatory expectations related to sub-visible particles.

SP Scientific's program of free educational webinars delivered by industry experts are devoted to lyophilization, freeze-drying and related topics.

LyoLearn webinars follow a 45-minute format for the presentations with a Q&A session immediately afterwards.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Methods for Evaluating Lyophilized Product
SP Scientific, a world leader in freeze drying technology, has announced a new LyoLearn webinar that will discuss standard methods for evaluating lyophilized products.
Tuesday, December 07, 2010
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos